The share price of the American biotechnology company Ginkgo Bioworks, which entered the New York Stock Exchange less than a month ago, is being driven by accusations of fraud.According to the activist fund Scorpion Capital, the company's management, in conjunction with some shareholders, lied and is lying to investors about the company's management in order to inflate the share price.The company, in which a Czech family office (an institution focused on the process of managing family assets - editor's note) has invested in the past, denies this.“Ginkgo Bioworks is a colossal scam.It is a Frankensteinian amalgamation of the worst frauds of the last twenty years.It's rare to see a company with a market value of $23 billion create a scheme of related companies around itself in the US market, as Ginkgo has done.It's simply the American equivalent of China Hustle," Scorpion Capital said in its 175-page presentation, referring to a TV documentary that described fraud by Chinese companies listed on the US stock market.In its investigation, the fund concluded that most of Ginkgo's income is the result of accounting gimmicks and a network of companies, or rather empty boxes, connected to Ginkgo through different persons and the same shareholders.In addition, this is income that is only accounting, so no money has arrived on the accounts of the Ginkgo company.The Scorpion fund, which specializes in speculating on the decline in share prices of troubled companies, based its allegations on, among other things, conversations with current and former employees of Ginkgo and related entities.Ginkgo CEO Jason Kelly denied the allegations in a statement sent to the media.Startups Twelve-fold return.Czech bpd partners are looking forward to a hundred million dollar exitFrom last Wednesday, when the Scorpion report came out, to the end of Monday's trading, the share price of the Ginkgo company fell by about a fifth.The market value thus fell to 18.5 billion dollars.However, it's still very high considering that the company's revenue for the 2020 fiscal year reached just under $77 million.The loss was $127 million.This year, revenue should reach $175 million.Among Ginkgo's largest shareholders are the hedge fund Viking Global Investors, the family office Cascade Investment of Microsoft co-founder Bill Gates, and the investment firms General Atlantic and Baillie Gifford.Among the smaller shareholders in the last four years was the company BT Ventures, which is supported by the Czech family office bpd partners (manager of the assets of billionaires Vasil Bobela, Petr Pudil and Jan Dobrovský - editor's note) and the Brůžk family.BT Ventures has not yet sold its stake, although earlier reports said it was considering doing so."Volatility in share price is common for similar companies after going public.Of course, we are carefully monitoring and analyzing the situation," said Pavel Brůžek, one of the founders of BT Ventures, when asked by E15.“As a minority shareholder who entered Ginkgo Bioworks in a round called Series D, we have the same insight into the company's management as other shareholders, and our ability to verify the information you mention is quite limited.Despite all the mentioned information, we still consider Ginkgo Bioworks to be a stock with a valuation and interesting growth potential," added Brůžek.Video is being prepared ... Investments of 2021: Commodities, stocks, cryptocurrencies and bonds • VIDEO VideohubGinkgo Bioworks was founded in 2009 by a group of scientists from the Massachusetts Institute of Technology.It deals with the production of genetically modifiable organisms, bacteria, which can further be used for industrial purposes.In the chemical and pharmaceutical industry, for example, it promises a significant reduction in costs and at the same time more environmentally friendly procedures.The well-known investment firm Citron Research also commented on the accusations.In her comment, she stood up for the revelation of Scorpion Capital.Citron also characterized the events surrounding Ginkgo Bioworks as a scheme that aims to drive the share price up, from which shareholders who bought the securities much cheaper when the company was not yet listed would benefit the most.Try our calculators and compare your salary with other residents of the Czech Republic.Net salary Nursing allowance Net profit Self-employed Sickness Retirement age Pension amount Maternity Housing allowance Parental allowance Mortgage calculator Long-term care allowance Personal assessment base Life insurance Wage replacement